24 November 2021 in Molecular Biology Reports
31 December 2025 in Hacettepe Journal of Biology and Chemistry
Favipiravir is a nucleoside analog that is a selective and potent inhibitor of influenza virus RNA-dependent RNA polymerase (RdRp). This drug is considered to be a potential inhibitor of RNA viruses other than influenza due to its effect on the RdRp. In this study, we evaluated the effects of favipiravir on expression of interferon-related genes in alveolar epithelial cells (A549 and BEAS-2B) which produce various types of chemokines. The cytotoxicity and anti-RdRp activity of favipiravir were examined by MTT and virus minireplicon assays, respectively. Favipiravir strongly inhibited human (A/WSN/33-H1N1) and avian type of influenza (A/duck/Pennsylvania-H5N2) virus RdRp at nontoxic doses. The gene transcripts in the cells treated with different doses of favipiravir were analyzed by qPCR and immunoblotting. While CCL2, CAV1 and PRKCZ genes were among the most downregulated genes; IFNB1, IFNE and IL10 genes were the most upregulated in favipiravir-treated cells. The CCL2 and INFB1 transcripts were the most significantly differentiated by favipiravir treatment. The BEAS-2B cells were less sensitive to favipiravir-treatment compared to A549. From this result, it was concluded that favipiravir, while primarily inhibiting the viral RdRp, may also affect cellular interferon defense mechanisms and interfere with virus replication.